SAB Biotherapeutics (NASDAQ:SABS) is a clinical‐stage biotechnology company focused on the development of fully human polyclonal antibodies for the prevention and treatment of infectious diseases and oncology indications. The company’s proprietary GenAb® platform leverages transchromosomic bovines—genetically engineered cattle capable of producing high‐potency, human immunoglobulins at scale. This innovative approach enables rapid response to emerging pathogens and the generation of therapeutic antibodies that mimic natural human immune responses.
The company’s pipeline includes several product candidates targeting viral threats and cancer. SAB-185, a fully human polyclonal antibody therapy for COVID-19, has advanced through clinical trials, while SAB-301 and SAB-181 have been developed against Middle East respiratory syndrome (MERS) and Zika virus, respectively. In the oncology arena, SAB-183 is being explored as an immunotherapy for solid tumors, reflecting SAB Biotherapeutics’ broader strategy to apply its platform across multiple therapeutic areas.
Founded in 2014 and headquartered in Sioux Falls, South Dakota, SAB Biotherapeutics operates a state‐of‐the‐art research and cattle production facility where herd management, antibody collection, and purification occur under one roof. The company’s leadership team is led by CEO Randall J. Lanier, Ph.D., whose experience in immunology and therapeutic development guides SAB’s strategic collaborations and regulatory engagements. SAB has established partnerships with government agencies and global biopharmaceutical firms to accelerate its research and development programs.
Looking ahead, SAB Biotherapeutics aims to expand its manufacturing capacity and broaden its pipeline through both internal discovery efforts and external collaborations. By harnessing the GenAb platform’s versatility, the company seeks to address unmet medical needs in infectious disease outbreaks and cancer immunotherapy, positioning itself as a leader in next‐generation antibody therapeutics.
